Anthem Biosciences Limited (ANTHEM)
BSE
861.35
-11.65 (-1.33%)
Closed
Oct 9, 2026
Day's Range
833.00878.70
52 wk Range
579.45977.00
Financial Statements - ANTHEM - Anthem Biosciences Limited
Revenue
21.24B▲ 15.2%
Net Income
5.91B▲ 31.1%Net Margin 27.9%
EBITDA
9.79B▲ 30.1%
Free Cash Flow
6.33B▲ 6678.5%
Income Statement
| Period Ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Sales | 21.24B | 18.44B | 14.19B | 10.56B |
| Cost of Goods | 8.12B | 7.43B | 5.99B | 3.39B |
| Gross Profit | 13.12B | 11B | 8.19B | 7.17B |
 Operating Expense | - | - | - | - |
| Operating Income | 7.05B | 5.92B | 4.24B | 3.71B |
| Non-Operating Interest | - | - | - | - |
| Other Income Expense | - | - | - | - |
| Pre Tax Income | 8.24B | 6.56B | 4.77B | 4.97B |
| Income Tax | 2.32B | 2.05B | 1.10B | 1.12B |
| Net Income | 5.91B | 4.51B | 3.67B | 3.85B |
| EPS Basic | 10.55 | 8.035113 | 6.540303 | 6.858585 |
| EPS Diluted | 10.43 | 8.035113 | 6.540303 | 6.858585 |
| Basic Shares Outstanding | 561.13M | 561.61M | 561.61M | 561.61M |
| Diluted Shares Outstanding | 561.13M | 561.61M | 561.61M | 561.61M |
| Ebit | 8.30B | 6.66B | 4.86B | 5.05B |
| Ebitda | 9.79B | 7.53B | 5.61B | 5B |
| Net Income Continuous Operations | 8.24B | 6.56B | 4.77B | 4.97B |
| Minority Interests | - | - | - | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
